JP2023516381A - Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 - Google Patents

Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 Download PDF

Info

Publication number
JP2023516381A
JP2023516381A JP2022552782A JP2022552782A JP2023516381A JP 2023516381 A JP2023516381 A JP 2023516381A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2023516381 A JP2023516381 A JP 2023516381A
Authority
JP
Japan
Prior art keywords
oxo
fluorophenyl
oxy
carboxamide
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516381A5 (cg-RX-API-DMAC10.html
Inventor
シン,ジェシク
コ,ヨンオク
イ,ミンギ
キム,ヨンソク
チェ,スンジン
イム,ナジョン
キム,ミンファ
イ,ジュンヒョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellmarker Bio Co Ltd
Original Assignee
Wellmarker Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellmarker Bio Co Ltd filed Critical Wellmarker Bio Co Ltd
Publication of JP2023516381A publication Critical patent/JP2023516381A/ja
Publication of JP2023516381A5 publication Critical patent/JP2023516381A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
JP2022552782A 2020-03-03 2021-03-03 Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 Pending JP2023516381A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200026381 2020-03-03
KR10-2020-0026381 2020-03-03
PCT/KR2021/002622 WO2021177721A1 (ko) 2020-03-03 2021-03-03 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
JP2023516381A true JP2023516381A (ja) 2023-04-19
JP2023516381A5 JP2023516381A5 (cg-RX-API-DMAC10.html) 2024-03-12

Family

ID=77612768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552782A Pending JP2023516381A (ja) 2020-03-03 2021-03-03 Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物

Country Status (6)

Country Link
US (1) US20230099204A1 (cg-RX-API-DMAC10.html)
EP (1) EP4115887A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023516381A (cg-RX-API-DMAC10.html)
KR (1) KR20210111711A (cg-RX-API-DMAC10.html)
CN (1) CN115209900A (cg-RX-API-DMAC10.html)
WO (1) WO2021177721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP4011885A4 (en) * 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
KR20230144483A (ko) * 2022-04-06 2023-10-16 웰마커바이오 주식회사 Ron 돌연변이와 관련된 두경부암 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182274A1 (en) * 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
JP2022543250A (ja) * 2019-08-02 2022-10-11 ウェルマーカー・バイオ・カンパニー・リミテッド オキソ-ピリジン縮合環誘導体、およびそれを含む医薬組成物
JP2022554042A (ja) * 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101390076B1 (ko) 2006-11-08 2014-04-29 브리스톨-마이어스 스큅 컴퍼니 피리디논 화합물
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013155223A1 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
WO2016018087A1 (ko) * 2014-07-29 2016-02-04 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
CN107406492B (zh) * 2014-09-03 2021-12-24 井标记生物 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途
JP2023513675A (ja) * 2020-02-06 2023-04-03 ウェルマーカー・バイオ・カンパニー・リミテッド Kras変異に関連する癌の予防または治療のための医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019182274A1 (en) * 2018-03-08 2019-09-26 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
JP2022543250A (ja) * 2019-08-02 2022-10-11 ウェルマーカー・バイオ・カンパニー・リミテッド オキソ-ピリジン縮合環誘導体、およびそれを含む医薬組成物
JP2022554042A (ja) * 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance", ONCOTARGET, vol. 10, no. 13, JPN6025003442, 2019, pages 1320 - 1333, ISSN: 0005732661 *
"KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis", PNAS, vol. 116, no. 44, JPN6025003441, 2019, pages 22122 - 22131, ISSN: 0005732662 *
MICHELE L. BABICKY ET AL., ONCOGENE, vol. 38, JPN6025020442, 2019, pages 5599 - 5611, ISSN: 0005732663 *

Also Published As

Publication number Publication date
WO2021177721A1 (ko) 2021-09-10
EP4115887A1 (en) 2023-01-11
US20230099204A1 (en) 2023-03-30
EP4115887A4 (en) 2024-07-17
CN115209900A (zh) 2022-10-18
KR20210111711A (ko) 2021-09-13

Similar Documents

Publication Publication Date Title
EP4115887A1 (en) Pharmaceutical composition for prevention or treatment of cancer in which kras mutation and activated ron are present
US20230346790A1 (en) Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation
TW202529768A (zh) 癌症治療的療法
CA3110901C (en) Combination therapy for treating blood cancer
JP6147246B2 (ja) Akt及びmek阻害剤化合物の組み合わせ、及び使用方法
MX2014009303A (es) Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
WO2021018032A1 (en) Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
JP6526789B2 (ja) 組み合わせ療法
EP1885187B1 (en) Methods for treating drug resistant cancer
US20230241073A1 (en) Pharmaceutical composition for preventing or treating non-small cell lung cancer associated with ron mutantation, and method using same
US20230242521A1 (en) Pharmaceutical composition for preventing or treating pancreatic cancer associated with ron mutation and method using same
US20230076733A1 (en) Combination Therapy
Robert et al. 5 BRAF and MEK Inhibitors
HK1110477B (en) Methods for treating drug resistant cancer
HK1232877A1 (en) Association between 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione and an egfr tyr kinase inhibitor
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
HK1193754A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118